https://www.PR.com/ Latest news releases from PR.com for Thrombolex, Inc. Sat, 18 Apr 2026 21:45:40 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/963384 Mon, 16 Mar 2026 18:00:00 -0400 Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML). Thrombolex, a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led [PR.com] https://www.pr.com/press-release/963384 Thrombolex, Inc. https://www.pr.com/press-release/952068 Tue, 28 Oct 2025 12:00:12 -0400 THROMBOLEX™, Inc. presented the prespecified interim analysis from the first 50 patients in RAPID-PE during an Innovation Session at TCT, in San Francisco. [PR.com] https://www.pr.com/press-release/952068 Thrombolex, Inc. https://www.pr.com/press-release/941803 Wed, 25 Jun 2025 09:00:00 -0400 Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. [PR.com] https://www.pr.com/press-release/941803 Thrombolex, Inc. https://www.pr.com/press-release/924080 Mon, 28 Oct 2024 14:23:38 -0400 RESCUE-II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis without Post-Procedure Infusion in Treating Acute Pulmonary Embolism [PR.com] https://www.pr.com/press-release/924080 Thrombolex, Inc. https://www.pr.com/press-release/923707 Wed, 23 Oct 2024 12:45:00 -0400 Thrombolex, Inc. announced the enrollment of the first two patients in the RAPID-PE study using the BASHIR™ Endovascular Catheter for the treatment of acute pulmonary embolism by Dr. Ayman Iskander, interventional cardiologist at St. Joseph’s Health Hospital in Syracuse, NY. The RAPID-PE study is a single arm, multi-center post market study evaluating the safety and effectiveness of on-the-table [PR.com] https://www.pr.com/press-release/923707 Thrombolex, Inc. https://www.pr.com/press-release/916769 Tue, 30 Jul 2024 08:00:00 -0400 Thrombolex, Inc., an innovator in the development of advanced interventional medical devices for the treatment of thromboembolic disease, and Aidoc, a pioneering force in clinical AI, are pleased to announce a strategic partnership aimed at revolutionizing the treatment of acute pulmonary embolism (PE). This strategic collaboration will leverage Aidoc’s cutting-edge AI technology to accelerate patient identification [PR.com] https://www.pr.com/press-release/916769 Thrombolex, Inc. https://www.pr.com/press-release/904655 Mon, 22 Jan 2024 12:00:00 -0500 Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the BASHIR™ Endovascular Catheter for the treatment of acute intermediate-risk pulmonary embolism by Drs. Riyaz Bashir and Vladimir Lakhter, at Temple University Hospital, Philadelphia, Pennsylvania. [PR.com] https://www.pr.com/press-release/904655 Thrombolex, Inc. https://www.pr.com/press-release/903736 Tue, 09 Jan 2024 10:00:00 -0500 Thrombolex, Inc., announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™ S-B .035 Endovascular Catheters, which are comparable with an 0.035” guidewire. The BASHIR™ and BASHIR™ S-B Endovascular Catheters are 510(k) cleared for the treatment of acute pulmonary embolism (PE). [PR.com] https://www.pr.com/press-release/903736 Thrombolex, Inc. https://www.pr.com/press-release/898909 Tue, 24 Oct 2023 17:20:26 -0400 Thrombolex, Inc., announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the BASHIR™ Endovascular Catheter and small doses of tPA. The RESCUE trial also showed unsurpassed efficacy and safety in this patient population [PR.com] https://www.pr.com/press-release/898909 Thrombolex, Inc. https://www.pr.com/press-release/885020 Thu, 20 Apr 2023 18:00:00 -0400 Thrombolex, Inc. has received 510(k) clearance for use of the BASHIR™ and BASHIR™ S-B Endovascular Catheters for the treatment of acute pulmonary embolism (PE). [PR.com] https://www.pr.com/press-release/885020 Thrombolex, Inc. https://www.pr.com/press-release/881099 Mon, 06 Mar 2023 17:40:00 -0500 Marked reduction in segmental and main pulmonary artery occlusions shown in NIH-sponsored RESCUE trial with the BASHIR™ Endovascular Catheter in Patients with Intermediate Risk Acute Pulmonary Embolism. [PR.com] https://www.pr.com/press-release/881099 Thrombolex, Inc. https://www.pr.com/press-release/875260 Thu, 15 Dec 2022 18:02:41 -0500 Thrombolex, Inc. has been awarded a group purchasing agreement with Premier Inc., effective December 1, 2022. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BASHIR™ Endovascular Catheters. The family of BASHIR™ Endovascular Catheters offers a novel way of treating arterial and venous thrombosis through its hybrid [PR.com] https://www.pr.com/press-release/875260 Thrombolex, Inc. https://www.pr.com/press-release/874836 Thu, 08 Dec 2022 17:45:00 -0500 Thrombolex Releases the Results of the RESCUE Pivotal Trial for the Treatment of Acute Pulmonary Embolism (PE) with the BASHIR™ Endovascular Catheter. [PR.com] https://www.pr.com/press-release/874836 Thrombolex, Inc. https://www.pr.com/press-release/865536 Mon, 18 Jul 2022 16:00:00 -0400 Thrombolex today announced that its Board of Directors has named Michael Cerminaro Chief Executive Officer (CEO) of Thrombolex effective July 13, 2022, the date of the Company’s most recent Quarterly Board Meeting. Mr. Cerminaro will also retain his current title of President. Mr. Woodall, currently Chairman and CEO, will serve as Executive Chairman and transition the CEO role to Mr. Cerminaro, currently President [PR.com] https://www.pr.com/press-release/865536 Thrombolex, Inc. https://www.pr.com/press-release/853198 Mon, 17 Jan 2022 19:27:59 -0500 Thrombolex, Inc. – BASHIR™ Endovascular Catheters Show Dramatic Reduction in Thromboembolic Occlusions in Segmental Pulmonary Arteries of Patients with Acute Intermediate Risk PE: Interim Results of NIH-Funded RESCUE Trial [PR.com] https://www.pr.com/press-release/853198 Thrombolex, Inc. https://www.pr.com/press-release/845771 Thu, 14 Oct 2021 08:00:00 -0400 The BASHIR™ Endovascular Catheter (BEC) and the BASHIR™ Plus Endovascular Catheters (BASHIR™+ 10, BASHIR™+20, BASHIR™+30, BASHIR™+40) are hybrid devices that enable both mechanical and pharmacological treatment through use of an expandable infusion basket with the ability to infuse thrombolytics. These catheters are intended for the controlled and selective infusion of [PR.com] https://www.pr.com/press-release/845771 Thrombolex, Inc. https://www.pr.com/press-release/846198 Wed, 06 Oct 2021 09:21:00 -0400 Thrombolex, Inc. – BASHIR™ Endovascular Catheter Shows Marked Reduction in RV/LV Ratio and Thrombus Burden in Patients with Acute Intermediate-Risk PE [PR.com] https://www.pr.com/press-release/846198 Thrombolex, Inc. https://www.pr.com/press-release/845772 Wed, 29 Sep 2021 14:00:00 -0400 Thrombolex, Inc. continues to enroll in the pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE). This trial is conducted using the BASHIR™ and BASHIR™ S-B Endovascular Catheters (BEC) under an Investigational Device Exemption (IDE) from the FDA. The goal of RESCUE is to achieve an additional indication for use of the device in the treatment of PE. During the 2021 [PR.com] https://www.pr.com/press-release/845772 Thrombolex, Inc. https://www.pr.com/press-release/844934 Thu, 16 Sep 2021 18:00:00 -0400 THROMBOLEX, Inc. will be attending the VEINS Conference (Booth T8) and VIVA Physicians Conference (Booth #502) in Las Vegas, NV October 3-7. [PR.com] https://www.pr.com/press-release/844934 Thrombolex, Inc. https://www.pr.com/press-release/818592 Thu, 06 Aug 2020 16:30:00 -0400 THROMBOLEX™ Inc. has announced that it has enrolled the first patient in its pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE) using the BASHIR® Endovascular Catheter, under an Investigational Device Exemption (IDE) from the FDA. RESCUE is a prospective, single-arm, multicenter trial of pharmaco-mechanical catheter-directed thrombolysis (CDT) and will enroll up to [PR.com] https://www.pr.com/press-release/818592 Thrombolex, Inc. https://www.pr.com/press-release/816408 Tue, 07 Jul 2020 19:00:00 -0400 Thrombolex™ Inc. has announced that it was awarded a $3 million Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI) section of the NIH to fund their pivotal RESCUE trial under an IDE for the treatment of up to 125 patients with acute, submassive, pulmonary embolism at up to 20 centers in the USA. Dr. Brian Firth serves as the Principal Investigator on this SBIR [PR.com] https://www.pr.com/press-release/816408 Thrombolex, Inc. https://www.pr.com/press-release/807060 Thu, 05 Mar 2020 09:30:00 -0500 Thrombolex Bashir® Endovascular Catheter First-In-Man (FIM) Trial for Acute Pulmonary Embolism Confirms Early Safety and Feasibility and Impressive Reduction of Clot Burden - Results of FIM Trial presented at American Venous Forum (AVF) Annual Meeting [PR.com] https://www.pr.com/press-release/807060 Thrombolex, Inc. https://www.pr.com/press-release/806026 Wed, 19 Feb 2020 03:00:00 -0500 Temple University President, Richard Englert, and Vice President for Research, Michele Masucci, gathered colleagues to honor the University’s top inventors, and distinguished researchers at the third annual President’s Innovation Award Gala. Fueled by more than $279 million in annual research expenditures and 40,000 students, Temple’s innovation pipeline features a diverse mix of technologies and [PR.com] https://www.pr.com/press-release/806026 Thrombolex, Inc. https://www.pr.com/press-release/790854 Mon, 29 Jul 2019 08:03:00 -0400 Thrombolex, Inc. today announced the enrollment of the first patient in their Early Feasibility and Safety Study, investigating the Bashir™ Endovascular Catheter for the treatment of submassive pulmonary embolism (PE). The device was designed to quickly and safely dissolve thrombus and restore blood flow in patients with thrombotic vascular occlusions. The Bashir™ Endovascular Catheter includes an expandable [PR.com] https://www.pr.com/press-release/790854 Thrombolex, Inc.